Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > November 18, 2024
Daily News
November 18, 2024
- Japan’s Big 4 Drug Wholesalers Log 17.6% Operating Profit Growth
November 18, 2024
- MHLW Eyes Hiking Copay Cap to Curb Healthcare Spending
November 18, 2024
- Pfizer Japan Taps COO Hiroo Igarashi as New Skipper
November 18, 2024
- Dispensing Costs for Top LLPs Fall over 30% after Elective Care Rollout: Intage
November 18, 2024
- Shipment Curbs Growing for Strattera Generics amid Nitrosamine Issues
November 18, 2024
- Japan, US, Europe Trade Groups Urge Ishiba Govt to Scrap Off-Year Revisions
November 18, 2024
- MSD Files Silgard 9 for Male Use in Japan
November 18, 2024
- Pfizer’s JN.1 COVID Jabs for Children, Infants Now Available in Japan
November 18, 2024
- Kaken Snags Option Rights to Numab’s IBD Drug in Asia
November 18, 2024
Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…